Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19

ABSTRACT The SARS-CoV-2 coronavirus, which causes COVID-19, uses a viral surface spike protein for host cell entry and the human cell-surface transmembrane serine protease, TMPRSS2, to process the spike protein. Camostat mesylate, an orally available and clinically used serine protease inhibitor, in...

Full description

Bibliographic Details
Main Authors: Yuri Kosinsky, Kirill Peskov, Donald R. Stanski, Diana Wetmore, Joseph Vinetz
Format: Article
Language:English
Published: American Society for Microbiology 2022-04-01
Series:Microbiology Spectrum
Subjects:
COVID-19
antiviral pharmacology
camostat
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02167-21

Internet

https://journals.asm.org/doi/10.1128/spectrum.02167-21

Similar Items